Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PLX | US
0
0%
Healthcare
Biotechnology
30/06/2024
17/10/2024
1.09
1.10
1.11
1.08
Protalix BioTherapeutics Inc. a biopharmaceutical company engages in the development production and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States Australia Canada Israel Brazil Russia Turkey and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102 a therapeutic protein candidate for the treatment of Fabry disease; PRX-115 a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119 a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack New Jersey. Protalix BioTherapeutics Inc. is a subsidiary of Protalix Ltd.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
High Short-term Volatility
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
61.2%1 month
53.5%3 months
55.3%6 months
61.5%-
1.74
2.78
0.92
0.29
5.63
1.59
-0.10
-13.53M
80.16M
80.16M
-
-18.01
-39.20
-61.60
-43.49
20.34
4.45
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.12
Range1M
0.17
Range3M
0.36
Rel. volume
1.09
Price X volume
159.53K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Clearside Biomedical Inc | CLSD | Biotechnology | 1.15 | 85.96M | 2.68% | n/a | -168.27% |
CASI Pharmaceuticals Inc | CASI | Biotechnology | 5.43 | 83.95M | 0.56% | n/a | 167.26% |
PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.6 | 83.54M | 0.00% | n/a | 6.06% |
Aclaris Therapeutics Inc | ACRS | Biotechnology | 1.17 | 83.47M | 0.86% | n/a | 2.10% |
Ovid Therapeutics Inc | OVID | Biotechnology | 1.17 | 83.04M | -0.85% | n/a | 18.40% |
Ikena Oncology Inc. Common Stock | IKNA | Biotechnology | 1.71 | 82.52M | -0.58% | n/a | 6.36% |
SELLAS Life Sciences Group Inc | SLS | Biotechnology | 1.25 | 80.42M | 0.00% | n/a | 23.76% |
Audentes Therapeutics Inc | BOLD | Biotechnology | 3.03 | 80.16M | -0.33% | n/a | 0.47% |
IO Biotech Inc. Common Stock | IOBT | Biotechnology | 1.21 | 79.72M | 1.68% | n/a | 2.23% |
ALXO | ALXO | Biotechnology | 1.51 | 79.53M | -3.21% | n/a | 10.97% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 5.63 | 0.53 | Expensive |
Ent. to Revenue | 1.59 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 2.78 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 55.29 | 72.92 | Lower Risk |
Debt to Equity | 0.92 | -1.24 | Expensive |
Debt to Assets | 0.29 | 0.25 | Par |
Market Cap | 80.16M | 3.78B | Emerging |